瑞舒伐他汀与阿托伐他汀对急性冠脉综合征患者血脂与CRP 疗效的比较

摘要

Objective:To explore therapeutic effect of rosuvastatin and atorvastatin treatment on levels of lipoprotein and inflammatory factors in patients with acute coronary syndrome (ACS) .Methods :A total of 74 ACS patients , who were treated in our department of cardiology from Mar 2008 to Feb 2014 ,were selected .According to random number table ,they were randomly and equally divided into rosuvastatin group and atorvastatin group .Therapeutic effect on 24d after administration ,levels of low density lipoprotein cholesterol (LDL‐C) ,high density lipoprotein cholesterol (HDL‐C) ,interleukin (IL)‐18 and C reactive protein (CRP) before and four weeks after treatment were compared between two groups .Results:On 24d after treatment ,total effective rat of rosuvastatin group was significantly higher than that of atorvastatin group (83.8% vs .75.7% , P< 0.05);after four‐week treatment , compared with atorvastatin group ,there were significant reductions in levels of LDL‐C [ (1. 8 ± 0. 2 ) mmol/L vs . (1.4 ± 0.1) mmol/L] ,IL‐18 [ (1.8 ± 0.2) vs .(1.4 ± 0.1)] and CRP [ (1.9 ± 0.3) pg/ml vs .(1.4 ± 0.2) pg/ml],andsignificantriseinHDL‐Clevel[(1.4±0.2)mmol/Lvs.(1.9±0.3)mmol/L]inrosuvastatingroup,P<0.05 all .Conclusion:Rosuvastatin therapy can achieve better adjusting lipid and anti‐inflammation effect than those of atorvastatin in patients with acute coronary syndrome ,which is worth clinical extending .%目的：探讨瑞舒伐他汀与阿托伐他汀治疗对急性冠脉综合征（ACS）患者脂蛋白与炎性因子疗效的比较。方法：选择我院心内科于2008年3月～2014年2月收治的74例ACS患者，采用随机数字表法分为瑞舒伐他组和阿托伐他汀组，各37例。比较两组给药24h后的临床疗效，及治疗前及治疗4周后的低密度脂蛋白胆固醇（LDL‐C）、高密度脂蛋白胆固醇（HDL‐C）、白介素（IL）‐18及C反应蛋白（CRP）水平。结果：治疗24d后，瑞舒伐他组总有效率显著高于阿托伐他汀组（83.8％比75.7％， P＜0.05）；治疗4周后，与阿托伐他汀组比较，瑞舒伐他汀组LDL‐C [（1.8±0.2） mmol／L比（1.4±0.1） mmol／L]、IL‐18[（1.8±0.2） pg／ml比（1.4±0.1） pg／ml]、CRP [（1.9±0.3）比（1.4±0.2）]水平明显降低， HDL‐C [（1.4±0.2） mmol／L比（1.9±0.3） mmol／L]水平明显升高（P均＜0.05）。结论：急性冠脉综合征患者采取瑞舒伐他汀治疗，其疗效优于阿托伐他汀，有更佳的调脂、抗炎效果，值得推广。